Günter Köhler

BACKGROUND: The diagnosis of rare uterine leiomyosarcoma (uLMS) remains a challenge given the high incidence rates of benign uterine tumors such as leiomyoma (LM). In the last decade, several clinical scores and blood serum markers have bee…

Background: There are conflicting data regarding the detection rate of high-risk uterine sarcoma (HRUS) by endometrial biopsy. In addition, there are no studies in the literature on its impact on the chosen surgical approach and survival. M…

Purpose This is an official guideline, published and coordinated by the Germany Society for Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, DGGG). Because of their rarity and heterogeneous histopathology, …

Aims This is an official guideline published and coordinated by the German Society of Gynecology and Obstetrics (DGGG) and the Austrian Society of Gynecology and Obstetrics (OEGGG). Because of their rarity and heterogeneous histopathology, …

DNG hatte jedoch eine Reihe von endokrinologischen Eigenschaften, die die Substanz ganz speziell zur Behandlung der Endometriose qualifizierten. Dazu gehörten: spezifische Bindung an den Progesteronrezeptor, aber keine Bindung an Transportg…

The authors wish to clarify that analyses in the paper are based on the full-analysis set (FAS), excluding patients for whom data were unavailable. For the revised American Fertility Society (rAFS) score, data were unavailable in 9.5% of pa…

OBJECTIVES: To compare the efficacy and safety of dienogest at doses of 1, 2, and 4mg/day orally in the treatment of endometriosis. METHODS: An open-label, randomized, multicenter, 24-week comparative trial in women with histologically con…

Eight otherwise healthy women aged 17 to 38 years with endometriosis were treated with 2 mg of the progestin dienogest daily for 24 weeks. Blood glucose and plasma insulin were measured prior to and during an intravenous glucose tolerance t…

The effects of the progestational compound dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one) on liver metabolism have been studied in 101 otherwise healthy women with endoscopically proven endometriosis. The women aged 1…

Endometriosis in an important disease especially for girls and young women. It often causes chronic complaints and infertility, requiring an early endoscopic diagnosis for their prophylaxis and therapy. The characteristics of endometriosis,…

The effects of a new progestational compound, dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one) on lipid metabolism have been studied in 84 otherwise healthy women with laparoscopically proven endometriosis. The women, a…

Basal body temperature of 168 cycles have been measured in 20 infertile women (age 21-31 years) with endometriosis. There were 10.1% anovulatory cycles, and in 22.5% of the 151 biphasic cycles the hyperthermic phase lasted less than 11 days…

The pharmacology and the application in oral hormonal contraceptives of four new progestogens--gestodene, desogestrel, norgestimate, and dienogest--are described in a survey. Although derived from 19-norethisterone these progestogens exhibi…

Fifty eight fertile female volunteers between 20 to 45 years were enrolled in a clinical trial to evaluate the efficacy and tolerance of the progestin dienogest (17 alpha-cyanomethyl-17 beta-hydroxyestra-4,9-dien-3-one, VEB Jenapharm Jena G…

Dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one, VEB Jenapharm, Jena, GDR), an orally active 19-nortestosterone derivative, was used firstly in the treatment of endometriosis. 57 patients (age 17-45 years) have been ent…